21/09/2026
Ten years ago, many of the tools we now use in cancer care were far from routine.
Clinical genomics was difficult to access. Liquid biopsy was met with skepticism. Precision oncology was discussed more often than it was delivered.
Last Friday in Singapore, we brought together oncologists, primary care physicians, surgeons, researchers, healthcare leaders and partners to mark Lucence’s 10th anniversary and, more importantly, to look at what comes next.
Prof GILBERTO de lima LOPES Junior, Chief of Medical Oncology at Sylvester Comprehensive Cancer Center, opened the evening’s clinical discussion by examining the gaps that remain between advances in precision oncology and their impact on patients.
Dr Min-Han Tan, Founding CEO and medical director of Lucence, reflected on a decade of molecular profiling and how cancer care is moving beyond therapy selection towards earlier detection, screening and prevention.
The takeaway from the evening was clear: progress in cancer care cannot stop at finding better ways to treat cancer once it has declared itself. The opportunity ahead is to find cancer earlier, when there may be more we can do to change the trajectory of a patient’s life.
Thank you to the clinicians, scientists, healthcare leaders and partners who have been part of Lucence’s journey over the past decade, and who joined us in thinking about what the next decade of cancer care could look like.
